Once the strategies and tactics have been developed, a baseline survey will be conducted with 150 women in the CCA experimental group and 150 women in the control group. For the experimental group only, we will be conducting semi-structured short interviews. Additionally the following clinical assessments will occur for both the experimental and control groups at baseline and the 12 month visit: change in cardiovascular risk markers (lipids, fasting glucose, waist circumference, body-mass-index, blood pressure, hs-CRP, NT-proBNP, body fat analysis), vascular reactivity (endoPAT), and arterial stiffness measurement, quality of life (SF-36 Health Survey), depression (Center for Epidemiological Studies Depression Scale) and Duke activity status index. The patients' cardiovascular risk markers (Cr, Hba1C, Lipid panel or any other routing blood tests depending on physician), ordered as part of standard care will be recorded as well. Patients will be followed for 12 months for recurrent hospitalizations and deaths. Once the participants join the study, if randomized into the experimental group, they will be required to participate in one of the following activities: one-on-one interview, focus group, or joining the advisory board. The control group will only participate in the clinical assessments and a baseline interview (administration of questionnaires).